• Lucid Diagnostics director Dennis Matheis bought 245,000 common shares at a weighted average price of $1.
• Holdings rose to 1,033,443 shares following the purchase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001094891-26-000217), on May 21, 2026, and is solely responsible for the information contained therein.